|
Survival rate
|
IMRT (non-IGRT)
|
HT (IGRT)
|
95 % CI
|
p value
|
|---|
|
5-year OS
|
47.5 %
|
86.7 %
|
0.53 to 0.64
|
0.015
|
|
5-year DFS
|
39.3 %
|
73.8 %
|
0.40 to 0.74
|
0.146
|
|
5-year LRPFS
|
49.8 %
|
69.8 %
|
0.37 to 0.77
|
0.104
|
|
5-year LPFS
|
58.4 %
|
85.2 %
|
0.58 to 0.70
|
0.006
|
|
5-year RPFS
|
81.2 %
|
81.4 %
|
0.62 to 0.72
|
0.653
|
|
5-year MFS
|
82.6 %
|
80.1 %
|
0.62 to 0.72
|
0.892
|
- Abbreviations: DFS disease-free survival, HT helical tomotherapy, IGRT image-guided radiotherapy, IMRT intensity-modulated radiotherapy, MFS metastasis-free survival, non-IGRT non-image-guided radiotherapy, LRPFS locoregional progression-free survival, LPFS local progression-free survival, OS overall survival, RPFS regional progression-free survival
